ENDURING MATERIAL LEARNER NOTIFICATION

MED Learning Group
The DETECT Initiative in Early Alzheimer's Disease: Optimizing Collaboration and Multidisciplinary Care to Facilitate Timely Diagnosis
April 20, 2023 – April 20, 2024
Online

Acknowledgement of Financial Commercial Support
Eli Lilly

Acknowledgement of In-Kind Commercial Support
No in-kind commercial support was received for this educational activity.

Satisfactory Completion
Learners must listen to each self-directed audio recording while following along with the visual slides and complete an evaluation form to receive a certificate of completion. Your chosen sessions must be viewed in their entirety. Partial credit of individual sessions is not available. If you are seeking continuing education credit for a specialty not listed below, it is your responsibility to contact your licensing/certification board to determine course eligibility for your licensing/certification requirement.

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by Amedco LLC and MED Learning Group. Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Nurses (ANCC) Credit Designation
Amedco LLC designates this activity for a maximum of 1.00 ANCC contact hours.

Objectives - After Attending This Program You Should Be Able To
1. Provide an accurate and timely diagnosis of AD to allow for early disease management and/or referral to specialists.
2. Select and use the best therapeutic options for patients with AD based on up-to-date clinical data on established and emerging disease modifying therapies.
3. Employ best practices for multidisciplinary care coordination, workflows, and best practices for referral of patients.

Disclosure of Conflict of Interest
The following table of disclosure information is provided to learners and contains the relevant financial relationships that each individual in a position to control the content disclosed to Amedco. All of these relationships were treated as a conflict of interest, and have been resolved. (C7 SCS 6.1---6.2, 6.5)

All individuals in a position to control the content of CE are listed below.

First Name	Last Name	Commercial Interest: Relationship
Laura	Aibara	NA
Daniel	DaSilva	NA
Brad	Dickerson	Acadia, Alector, Arkuda, Biogen, Denali, Eisai, Genentech, Lilly, Merck, Takeda, Wave Life Sciences: Consultant
Matthew	Frese	NA
Christina	Gallo	NA
Debra	Gordon	NA
Jessica	McMullen	NA
Paul	Schulz	Hoffman-Laroche, Acadia, Lilly, AbbVie, Novartis, Janssen, Passage Bio: Contracted Research; Lilly, Biogen, Acadia: Advisor; Acadia, Lilly, Biogen: Speakers Bureau; Zymo, Amprion: Other

Jo	Shultz	NA
Lauren	Welch	NA

Questions? Email Certificate@AmedcoEmail.com